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A B S T R A C T
Coronary allograft vasculopathy is the current leading cause for late graft loss following cardiac transplantation. Its
pathogenesis is multifactorial, including immune, constitutional and genetic factors, metabolism, infection, as well
as potential injury from routine immunosuppressive therapy. Children represent a patient group with unique
differences: their pretransplant history rarely includes ischemic heart disease and risk factors for atherosclerotic heart
disease, but many are presensitized from use of allograft material during reconstructive cardiac surgeries. Compared
with older children and adults, infants and young children show significantly lower rates of graft vasculopathy that
may be related to the relative immaturity of their immune system.
This review summarizes the current concepts of coronary allograft vasculopathy derived mainly from animal models
and adult clinical observations. It provides an overview of confirmed risk factors and explains their interactions. The
characteristics and unique clinical findings among pediatric transplant recipients will be explored within the context
of recent, albeit limited, scientific investigations.
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Introduction
Coronary allograft vasculopathy (CAV) is anaccelerated form of arteriopathy affecting the
coronary vessels of both pediatric and adult heart
transplant (HTx) recipients.1,2 It is characterized
by heterogeneous intimal proliferation, medial
wall thickening, and progressive luminal
stenosis.3–5 Despite recent improvements in early
and midterm post-HTx survival, CAV develops in
approximately one third of pediatric patients
within 10 years of transplant and continues to be
an immutable barrier to longer-term graft sur-
vival.6 This review will outline the current patho-
physiologic understanding of this complex disease
process and detail commonly reported constitu-
tional, infectious, and immunogenetic risk factors
in order to provide a framework from which
current therapies have been and may be devel-
oped. While much of the following discussion will
focus on pediatric risk factors, the reader should be
cognizant that published data on childhood risk
factors is less robust than in adults. Therefore,
some factors may be notably absent not because
they are necessarily irrelevant in pediatrics, but
rather because of limited data or an unknown asso-
ciation with disease.
CAV Pathogenesis
CAV shares many aspects of its pathogenesis and
many risk factors with arteriosclerosis of the non-
transplanted heart.3 In adults, ischemic heart
disease is the leading cause necessitating heart
transplantation. In these patients, the partial per-
sistence of the atherosclerotic process after trans-
plantation partly explains the higher frequency of
CAV compared with children. However, the dif-
ference in incidence is only marginal when com-
paring adults with teenagers, an age group that in
nontransplanted individuals usually does not
experience significant atherosclerotic vascular
disease.7
In addition to these constitutional factors,
which include mainly genetic and metabolic pre-
dispositions, a large contribution to CAV stems
from the immune response toward an immuno-
logically foreign organ. The operative procedure
of transplantation from a deceased donor enhances
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this response. To further complicate matters,
immunosuppressive medications and certain infec-
tious complications of immune suppression also
contribute to CAV pathogenesis. These factors
show significant overlap and interaction as sche-
matically shown in Figure 1 and detailed in the
following sections.
Ischemia-reperfusion Injury and Early
Immune Activation
The process of CAV in HTx recipients can be
traced to the time of graft transplantation when
donor-derived factors, which may likely contribute
to future CAV, have already been activated.8
Because the basis for heart donation is brain death,
the vast majority of donated hearts have under-
gone a period of significantly impaired circulation
and oxygen delivery often including a cardiac
arrest. Inotropic support and fluctuations of the
blood pressure are common, if only transiently, in
many patients. Subsequent apoptotic processes in
the tissue and activation of the donor immune
system and coagulation are initiated, including
complement, macrophages, and thrombocytes. In
addition, the process of brain death is associated
with multiple neurohormonal changes that may
adversely affect the coronary endothelium. Imme-
diately following brain death, circulating plasma
catecholamines markedly rise resulting in an
imbalance between oxygen delivery and consump-
tion.9,10 The resulting ischemic damage to the
graft leads to impaired integrity of the endothe-
lium and activation of the innate immune system11
causing endothelial alteration that persists post-
HTx.12,13 Following organ harvest, a period of cold
ischemia further contributes to this process and
especially enhances the disturbance in the endot-
helial cell function and the vessel wall integrity.14
In animal models, loss of smooth muscle cells
(SMCs) in the intima media at this stage is signifi-
cantly associated with the degree of later CAV.15 A
Figure 1. Overview of the pathogenetic factors of CAV and their interaction: Arrows symbolize enhancing effects, bars
inhibition. Ischemia-reperfusion injury includes damage to the endothelium facilitating macrophage invasion and leading to
exposure of graft antigens and activation of the complement system. This triggers an early response of the adaptive immune
system, which is enhanced if preformed graft specific antibodies are present, but also yields their development if no
appropriate immune suppression is introduced. Adverse effects of the immune suppressants include enhancement of
constitutional factors of atherosclerosis and increased risk for infections with negative impact on CAV. Viral infections under
immune suppression may enhance antibody production (Epstein-Barr virus) and have additional direct effects on endothe-
lium integrity (cytomegalovirus). Formation of plaques in the lumen perpetuates itself through increasing shear stress and
further disturbance of the endothelial integrity and subsequent enhanced immune response. mTOR inhibitors have antipro-
liferative effects on small muscle cell delaying the progression of graft vasculopathy. For details, see text.
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recent study observed the SMC reduction to occur
in two waves, one at the initial day post-HTx and
one 7 days later.16 The decrease of SMC density
occurred significantly less in absence of neutrophil
granulocytes (NCs).
These models confirm the current understand-
ing of the early events: preexplantation damage
and preservation-associated ischemia induce dis-
turbed integrity of the endothelial barrier17 pro-
moting invasion of components of the innate
(NCs, macrophages) and adaptive immune system
in both donor and recipient.4,18 Apoptosis occurs
in various cells in the intima yielding exposure of
human leukocyte antigen (HLA) and other anti-
gens17 that are recognized and processed by the
recipient adaptive immune system including both
CD8 and CD4 positive T cells18 and B cells.19 At
the same time, a highly immunogenic environ-
ment persists within the graft through activation
of the complement and the coagulation system and
secretion of cytokines and chemotactic factors by
the injured endothelium.14 Microscopic changes
within the vascular wall accompanying these pro-
cesses include interstitial fibrosis, invasion of NC,
macrophages and lymphocytes, primarily reduced
numbers and secondarily increased proliferation
of SMC, and infiltration of lipids with formation
of foam cells.4,16
Mechanical Factors and Atherosclerotic Impact
Once changes are initiated, the vessel narrowing,
plaque development, and local activation of
thrombocytes perpetuates the endothelial injury.
Shear stress associated with the altered vessel
geometry and perfusion hemodynamics is
further enhanced by increased arterial blood
pressures.20–22 The latter is a very common finding
in post-HTx patients. In children, hypertension is
often attributed to the immunosuppressive medi-
cation (steroids, calcineurin inhibitors [CNI])23
but is also due to progressive renal impairment as
observed in the majority of patients.
Mammalian target of rapamycin inhibitors
sirolimus and everolimus play an ambivalent role
in the pathogenesis of CAV: their antiproliferative
capacity does not only impair the adaptive
immune response but additionally reduces prolif-
eration of SMC and NC, hampering the progres-
sion of the vascular narrowing. On the flipside,
particularly in combination with CNI, the major-
ity of patients experience an unfavorable shift in
plasma triglyceride and cholesterol levels and pro-
file,23 increasing the risk for development of
atheroma-associated vasculopathy. Similar con-
cerns accompany other immune suppressive
agents. As described previously, steroids and CNI
induce hypertension in a significant proportion of
patients through direct effects but also secondary
to renal injury. Both drugs may also alter metabo-
lism leading to less favorable lipid profiles and
development of diabetes mellitus.23 However, the
use of synergistic effects in combined immunosup-
pressive regimens was found to reduce incidence
of CAV24–26 with the latest trials showing less new
development and progression of CAV when com-
bining a CNI with an mammalian target of rapa-
mycin inhibitor compared with mycophenolate.27
The adverse effect of infection, particularly virus-
induced enhanced generation of antibodies against
the graft, will be discussed later. Finding the right
balance between sufficient immune suppression
and adverse effects of the medication is therefore
crucial, but often challenging.
Chronic Rejection and Antibody-mediated
Immune Response
In any organ transplantation not originating from
an identical twin, the alloimmune response occurs
from the moment of reperfusion of the organ.
Significant concentrations of preformed antibod-
ies against the donor HLA or blood group anti-
gens induce immediate massive activation of all
arms of the immune system, a situation clinically
experienced as “hyperacute rejection.” Antibody-
mediated activation of the complement system
leads to direct graft damage but also chemotaxis,
attracting antigen presenting cells as well as lym-
phocytes including CD8+ cytotoxic T cells. Sur-
faces covered in antibodies are opsonized to
antigen presenting cells facilitating activation of
the adaptive immune system. This includes gen-
eration of antigen specific CD4+ T cells, B cells,
and plasma cells and yields further antibody pro-
duction and direct cytotoxic effects on the graft.
Consistent with findings in adults28 and other
transplanted organs,29 clinical studies in heart
transplanted children found not only a higher
mortality in presence of donor-specific HLA
antibodies (DSAs) but a higher incidence and
accelerated progression of CAV.30–33 Compared
with adults, development of DSA is less frequent
in children and associated with older age at
transplant.34
Multiple investigators have linked acute
allograft rejection with pediatric CAV,24,35 particu-
larly recurrent rejection during the first post-HTx
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year.2,36 In the Pediatric Heart Transplant Study
group analysis, Pahl and colleagues found that two
or more episodes of acute rejection in the first year
correlated with CAV.37 Late rejection (>1 year
post-HTx), including that associated with hemo-
dynamic compromise, is also a well-established
risk factor for CAV development.2,24,36,38–40 In a
large, single-center experience, Mulla and col-
leagues reported that both frequent (regardless of
severity) and severe episodes (even in the absence
of other rejection episodes) of late rejection are
independent predictors of CAV development, and
the resulting CAV can have a rapid onset and
accelerated course.38
Most of these studies have not investigated the
presence of DSA in their patient cohorts. Devel-
opment of DSA is associated with the frequency of
acute cellular rejection.41 In part, the detrimental
effect of repeated acute cellular rejection may be
mediated through de novo DSA. However, graft
vasculopathy occurs in absence of DSA. The
development of DSA as well as repeated acute
rejection may both be surrogates for insufficient
suppression of the immune system. Every episode
of rejection will, to some extent, result in an
episode of vascular damage comparable with the
previously described cascade during reperfusion
and the early post-HTx phase.
Genetic Predispositions
Variations in small sections of DNA, including
single nucleotides, between individuals that occur
with some regularity in the human population—
typically at least 1%—are known as genetic poly-
morphisms.42 The presence of a polymorphism
does not imply that it is pathologic, and much
research is currently ongoing to determine which
of these naturally occurring genetic variations may
be disease-causing. In recent years, an increasing
awareness of potentially pathologic polymor-
phisms affecting the inflammatory response has
led to several publications describing the role of
polymorphisms in determining the risk of CAV.
Because there have been no large-scale pediatric
publications examining polymorphisms and CAV,
the following discussion will review currently
available adult data assuming some pediatric rel-
evance to encourage new hypothesis-driven
investigations.
Immune System Polymorphisms
Intracellular adhesion molecule-1 (ICAM-1) is
an adhesion molecule present on the surface of
leukocytes and endothelial cells. When stimulated
by inflammatory cytokines, ICAM-1 expression is
markedly increased.43 When Borozdenkova et al.
studied ICAM-1 polymorphisms in both HTx
donors and recipients, they found that donor
hearts expressing a particular ICAM-1 polymor-
phism had significantly decreased incidence of
CAV at 2 years post–orthotopic heart transplant.44
Interleukin-6 (IL-6) is a proinflammatory
cytokine released by myocardial and endothelial
cells.45,46 It has many effects that may contribute
to the development of CAV including SMC
growth,47 production of C-reactive protein,48
modulation of endothelial permeability,49 and trig-
gering neutrophil oxidative burst.46 The IL-6 gene
is known to be polymorphic with a single nucle-
otide exchange resulting in a phenotype with
increased IL-6 production.50 Densem and col-
leagues sequenced adult HTx recipients and found
that being homozygous for the high-production
IL-6 allele was significantly associated with an
earlier onset of CAV.51
Transforming growth factor-beta 1 (TGF-b1) is
a cytokine that influences the accumulation and
function of leukocytes and fibroblasts at sites of
injury while enhancing production of extracellular
matrices,52 which may contribute to the develop-
ment of CAV. However, TGF-b1 also inhibits
smooth muscle and endothelial cell proliferation,53
which may be protective against CAV. The gene
encoding TGF-b1 has multiple polymorphisms,
and, as such, reports on the effects of these poly-
morphisms are contradictory. Holweg and col-
leagues found that in HTx recipients, a specific
polymorphism at locus site +869 was a risk factor
for accelerated CAV, while a polymorphism at
locus site +915 was not a significant predictor.52 To
the contrary, Densem and colleagues found
directly opposing results.54 The explanation for
this discrepancy is unclear, but nevertheless,
TGF-b1 appears to have a role in the pathogenesis
of CAV, and additional studies may further eluci-
date its significance.
Tumor necrosis factor-alpha (TNF-a) is a
cytokine released primarily by macrophages that
initiates a host of responses that can precipitate
coronary endothelial dysfunction,55,56 and some
CAV patients have been found to have high levels
of circulating TNF-a.57 However, when Densem
and colleagues evaluated the influence of TNF-a
polymorphisms on CAV development, they found
no relationship between recipient or donor geno-
type and CAV development, despite a significant
proportion of recipients and donors having high
Congenit Heart Dis. 2012;7:312–323
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TNF-a producing genotypes.55 In contrast, Tern-
strom and colleagues studied recipient TNF-a
and its linked cytokine gene, TNF-b,58 finding an
increased CAV prevalence and decreased 3-year
post-HTx survival among patients homozygous
for high cytokine producing polymorphisms of
either TNF-a or TNF-b. The discrepant results
between the two studies may be due to method-
ologic differences. While more compelling data is
needed, polymorphisms in TNF-a and TNF-b
could become important pretransplant markers
with TNF-a suppression as a potential therapeutic
target in at-risk recipients.
Coagulation and Thrombocyte Activation
Alterations in fibrinolytic activity may also be
important in CAV intimal proliferation as the
involved enzymes promote vascular cell migration,
cellular infiltration, and matrix regeneration.59
Enhanced fibrinolytic activity can result from
excessive tissue plasminogen activator (TPA) or
decreased activity of plasminogen activator
inhibitor-1 (PAI-1), a TPA inhibitor.60 Polymor-
phisms of both the TPA and PAI-1 genes have
been previously described.60–62 In one such study,
Benza and colleagues60 found significantly
increased freedom from CAV at 24 months for
PAI-1 high-expression homozygotes (100%
freedom) and heterozygotes (92%) compared with
low expression homozygotes (45%). No associa-
tion was found between TPA polymorphisms and
CAV. In a recent follow-up study, the same inves-
tigators corroborated their previous findings and
demonstrated severe CAV in transplanted PAI-1
knockout mice.59 Thus, PAI-1 activity appears to
prevent CAV development and may be a future
therapeutic target.
Platelet-derived growth factor (PDGF) and
vascular endothelial growth factor (VEGF) both
regulate differentiation of vascular progenitor
cells.63 PDGF regulates progenitor cell differen-
tiation into SMCs, while VEGF regulates differ-
entiation into endothelial cells. Both factors may
contribute to CAV pathogenesis by expanding
sites of coronary injury through smooth muscle
and endothelial cell proliferation.64 Both genes
have polymorphisms at multiple sites.65,66 Tambur
and colleagues64 recently demonstrated that spe-
cific PDGF and VEGF polymorphisms were sig-
nificantly associated with an increased incidence of
CAV and decreased 3-year patient survival.64
The renin-angiotensin system has been
postulated to be a significant contributor to
the pathogenesis of CAV,67 and inhibition of
the renin-angiotensin system is now standard
therapy to prevent progression of CAV.68,69 A com-
ponent of that system, angiotensin converting
enzyme (ACE) has well-recognized polymor-
phisms, ACE-D and ACE-I, in humans,70 and a
specific genotype (ACE-DI) may increase athero-
sclerotic coronary disease and myocardial infarc-
tion in non-HTx adults.71,72 Pethig and colleagues
ACE genotyped 146 patients and serially assessed
them for onset and progression of CAV finding
that the three ACE genotypes had differing free-
doms from CAV by 6 years post-HTx.73 In ACE-II
and ACE-DI patients, freedom from CAV was
85% and 77%, respectively, while ACE-DD
patients had only a 55% freedom from CAV (P =
0.015). Cunningham and colleagues74 evaluated
donor ACE polymorphisms and found ACE-DI
grafts had significantly increased prevalence of
CAV.74
Clinical Relevance
The current role of genetic polymorphisms in
clinical decision making is very limited, and, with
few exceptions, the study of polymorphisms has
been limited to single genes. However, multiple
inflammatory pathways and cytokines interact
during the inflammatory response. Given the
complex interplay and high level of redundancy of
the immune system, understanding how a single
polymorphism modulates expression of a single
cytokine adds little to understanding how the
inflammatory cascade affects CAV pathogenesis.
Until studies evaluate large numbers of patients
comparing both genetic and nongenetic risks of
CAV, the clinical utility of polymorphisms for risk
stratification or treatment guidance will remain
limited.
Metabolism
While hypercholesterolemia is a risk factor for
CAV in adult patients and treatment with statins
may ameliorate its effects,75 cholesterol levels have
not been associated with CAV in pediatric
patients. Nonetheless, hypercholesterolemia is
prevalent in pediatric HTx patients, particularly
those on cyclosporine immunosuppression, and
statin therapy decreases both low-density lipopro-
tein cholesterol and total cholesterol levels in
these patients.76,77 In a single-center study by
Mahle and colleagues, treatment with pravastatin
in post-HTx children was associated with a lower
incidence of CAV.39 As high low-density lipopro-
tein cholesterol has been associated with coronary
disease in adults, including CAV, so, too, has low
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high-density lipoprotein cholesterol.78,79 A recent,
small pediatric study demonstrated an association
between low serum levels of high-density lipopro-
tein cholesterol and CAV in patients already on
statin therapy.80 However, small patient numbers
and an abnormally early onset of CAV in these
study patients limit the generalizability of these
results to a larger pediatric HTx population.
While the relative contribution of cholesterol
chemistry to pediatric CAV is unclear, because of
the beneficial effects of statins on CAV noted in
adult studies their use has nevertheless become
routine in many pediatric transplant centers.
Finally, elevated plasma homocysteine (Hcy)
levels are a recognized independent risk factor for
coronary atherosclerosis.81–83 Both adult and pedi-
atric HTx patients have been demonstrated to
have elevated plasma Hcy.84,85 Further, adult HTx
recipients with severe CAV have significantly
higher plasma Hcy levels when compared with
HTx recipients without evidence of CAV.86,87 No
association between pediatric Hcy levels and CAV
has been established. The exact mechanism
through which Hcy affects CAV remains unclear;
however, Hcy is known to damage vascular endot-
helium through prooxidative pathways leading to
impaired endothelial vasodilation and intimal
hyperplasia.86,88,89 Treatment of both adult and
pediatric patients with folic acid has been shown to
decrease Hcy levels in patients with abnormally
high Hcy levels.90,91 In adults, this led to improved
survival 7-years posttreatment, although the
benefit may not be exclusively related to a decrease
in cardiovascular events.92 Hcy and treatment of




The role of cytomegalovirus (CMV) infection in
pediatric CAV remains controversial. CMV may
contribute to atherosclerotic plaques by modulat-
ing chronic inflammation in arterial walls.93 A
similar process may contribute to CAV lesions in
transplanted patients. In adults, multiple studies
have demonstrated an increased risk of CAV after
both CMV seroconversion and symptomatic
CMV infection.94–97 Notably, most adult data cites
“CMV mismatch,” a CMV-negative recipient of a
CMV-positive heart, as a CAV risk factor. A large,
single-center retrospective pediatric study demon-
strated that recipients who are CMV-positive prior
to transplant have a significantly higher rate of
CAV.98 Post-HTx CMV replication appears to
impair recipient endothelial function, and this
may provide a substrate for the development and
progression of CAV.99 A recent clinical study
evaluating intravascular ultrasound as a modality
to detect CAV found that CMV-positive patients
had significantly increased coronary maximal
intimal thickness compared with CMV-negative
patients.35 To the contrary, a recent multicenter
study of 1568 patients from the Pediatric Heart
Transplant Study group found no correlation
between donor or recipient CMV status and
CAV.100 These discrepant results may be partially
explained by differences in the proportion of
infants in each study, differences in CMV prophy-
laxis and differences in CAV detection methods. A
definitive role for CMV infection in the pathogen-
esis of pediatric CAV remains unclear.
Non-CMV Viral Endomyocarditis
Other viral endomyocardial infections have also
been associated with CAV. In a large study of pedi-
atric HTx patients, polymerase chain reaction
identification of viral genome in myocardial biop-
sies, particularly adenovirus, was associated with
adverse clinical events including increased rejec-
tion, graft loss, and early CAV development.101,102
Moulik and colleagues recently found that viral
endomyocardial infection is an independent pre-
dictor of graft loss in children likely secondary to
premature development of CAV.103 Historically,
many of these viruses have been causally linked to
acute rejection that can accelerate CAV (as previ-
ously described). It is unclear whether the viruses
themselves led to the development of CAV, or if
CAV was indirectly associated with virally medi-
ated rejection. In the study by Moulik et al., par-
voviral endomyocarditis was not associated with
rejection but was a significant risk factor for
CAV.103 The precise mechanisms by which viral
infections are associated with CAV, whether inde-
pendent of rejection or not, remain elusive.
However, many investigators suspect these active
myocardial viruses may lead to an inflammatory
state that potentiates ongoing coronary inflamma-
tion and subsequent CAV. In this setting, natural
killer (NK) cells may be important mediators of
CAV. Graham and colleagues developed a model
for CAV using post-HTx mice that lacked func-
tioning B and T cells.104 Virally infected mice sub-
sequently developed CAV, while noninfected mice
did not. Furthermore, infected mice in which NK
cells were depleted had a significantly lower inci-
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dence of CAV supporting the role of NK cells in
virally mediated CAV development.
Constitutional Factors
Hypertension
Hypertension is a well-established risk factor for
cardiovascular disease in adults.105,106 In concor-
dance with the pathophysiologic mechanisms
described previously, hypertension is significantly
associated with CAV in post-HTx adults,107 and
treatment with antihypertensive medication delays
CAV progression.108 Despite the lack of published
data for pediatric CAV, given its strong association
with coronary disease in other populations, blood
pressure control is a mainstay of post-HTx therapy.
Age
Compared with adults, the cited incidence of CAV
is lower in children with reported 5-year freedom
from CAV of 50%109 and 85%110 in adult and pedi-
atric transplant recipients, respectively. Pahl and
colleagues demonstrated that recipient age was a
relative risk for CAV. They found that a patient
aged 12 years at transplant had a 2.9-fold
increased likelihood of developing CAV compared
with a child transplanted at 5 years.37 This cor-
roborates data from other studies showing an
increased incidence of CAV among older age trans-
plant patients.40 The incidence of CAV in adoles-
cent patients is similar to adults.6 As a corollary,
there is a lower risk of CAV in infant transplant
recipients.35,111 The higher freedom from CAV
in pediatric patients may be related to a lack of
donor/recipient atherosclerotic risk factors
or preexisting coronary endothelial injury that
usually predisposes adult patients to an increased
incidence of disease.7 As such, older donor age has
also been recognized as a risk for pediatric CAV
with incremental increases as donor age increases
to an ultimate threefold increase if using donors
>30 years old compared with younger donors.37
This may be partially attributable to older donors
frequently having increased cardiovascular risk
factors for atherosclerosis, but in addition, intact
immune function within the donor myocardium
may affect endothelial function after transplanta-
tion thereby increasing the potential for donor-
mediated CAV.37 Detection methods may also
affect reported frequencies of disease as widespread
use of intravascular ultrasound has significantly
increased detection rates among adult patients.
Pediatric patients, especially infants and tod-
dlers, are immunologically privileged in the
setting of organ transplantation due to various
immaturities of the immune system reflected in an
annual CAV incidence of only 3% in children
transplanted in the first year.6 Children demon-
strate a decreased incidence of immune-mediated
endothelial injury,7 lack immune memory,112 are
unable to mount T-independent B cell immune
responses under 2 years old,113 are less likely to
develop donor-specific HLA antibodies post-
HTx,34 and are able to persistently tolerate blood
group incompatible organs.114,115 Thymectomy,
which routinely occurs in children with congenital
heart disease for reasons of surgical access, may
also contribute to the better graft acceptance of
infant recipients. The thymus plays a crucial role
in the development of adaptive immunity and self-
tolerance, and this procedure alters the total
number and the phenotype of T cells for many
years.116,117
Retransplantation
Although patients retransplanted for CAV fare
better than those retransplanted for early graft
failure, overall survival after pediatric retransplan-
tation is inferior to survival after primary trans-
plant.118 The International Society for Heart and
Lung Transplantation 2010 pediatric HTx report
found that retransplantation was significantly
associated with early onset CAV.6 The reasons for
this are not completely clear; however, the propor-
tion of sensitization against HLA or minor anti-
gens is likely higher due to the exposure to
nonself-antigens and the previous development of
a “successful” immune response against the first
graft. Further, the higher likelihood of cofactors
having developed through years of immune sup-
pression and associated adverse events may con-
tribute. In particular, children with early graft
failure show poor graft survival following retrans-
plantation in registry data;6 however, this is likely
impacted by their overall poorer clinical condition
going into the surgery.
Summary
CAV pathogenesis represents the complex inter-
play of a variety of factors. Medical intervention
for one factor may increase the risk of another
developing or worsening. Close monitoring of the
various contributors to CAV is required and
therapy must be adapted to changes in the balance
of risk factors. The intensity of immune suppres-
sion needs to be carefully balanced with potential
adverse effects of the medication. Contribution of
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altered lipid profiles, arterial hypertension, and
diabetes mellitus, whether caused by genetic pre-
disposition or subsequent to medication, have to
be addressed by appropriate medication. Infec-
tious disease monitoring as adapted in the recent
decade allows more timely intervention when
required. Donor-specific antibodies represent a
major contribution to CAV; however, despite
increasing evidence that acute antibody-mediated
rejection can successfully be treated with invasive
antibody removal and therapies to inhibit antibody
development, the impact of these treatments on
the progression of CAV remains indeterminate.
CAV remains the leading challenge for long-
term graft survival. An incomplete understanding
of its pathogenesis has limited the development of
therapies directed at process reversal or avoidance.
Further study, particularly in the pediatric HTx
population, is necessary to better elucidate mecha-
nisms of disease and potential targets for future
therapeutic intervention.
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